Silence Therapeutics raises five million pounds

published 29 November 2012

Biotechnology firm Silence Therapeutics announced a five million pound placing to Henderson Global Investors and Ora Capital.

New shares were placed at 2.5p representing a discount of around 19% to the market price.

Funds raised will be used to expand the group's research activities in short interfering RNA or ribonucleic acid and micro RNA therapies, it said.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

The group specialises in RNA interference therapeutics or 'gene silencing', which can shut down or control faulty genes for the treatment of cancer and other diseases.

"The proceeds of the subscription will enhance the company's financial position and provide it with sufficient cash resources to fund the business well into 2014, even without generating any revenue," Silence said in a company statement.

The group also confirmed that shareholder Robert Keith has given written notice to convert his £1m loan note into 200,000,000 new ordinary shares at 0.5p per share bringing his stake holding to just over 26%.

Director of Corporate Strategy Ali Mortazavi said: "We are delighted to welcome Henderson as a significant shareholder in Silence. Along with further support from our existing shareholders, the company is now ideally placed to take advantage of the new wave in RNAi therapeutics."

Shares in Silence soared 12.5% to 3.60p at 13:30.